Gregory Pelton, M.D.
Assistant Professor of Clinical Psychiatry (in Neurolology and in the Sergievsky Center)
Attending, Late Life Depression Clinic,
New York State Psychiatric Institute
Attending, Memory Disorders Clinic,
New York State Psychiatric Institute
Assistant Attending in Psychiatry,
Columbia University Medical Center
Clinical Research in adults over 50 years old.
1- A primary area of research involves studying the interface between depression and cognitive impairment (DEP-CI) in the elderly from both a treatment and pathophysiological perspective. The work includes both NIH funded and investigator initiated, industry sponsored clinical treatment trials. Prospective studies, both active and recently completed in patients with DEP-CI, but not dementia, include examining: i) acute antidepressant treatment effects on mood and cognitive performance, ii) long-term antidepressant treatment effects on mood and likelihood of developing Alzheimer’s disease (AD), iii) both acute and long-term effects of antidepressants alone or in combination with the memory enhancing medication donepezil or memantine, on mood, cognitive performance, and likelihood of developing AD.
2- As a co-investigator: i) evaluating the sensitivity and specificity of clinical features, neuropsychological test results, and brain imaging abnormalities in predicting the development of AD in cognitively impaired patients who do not initially meet criteria for dementia; ii) evaluating both the acute and long-term usefulness of various medications (e.g. antidepressants, atypical antipsychotics, lithium) in treating patients with agitation/aggression and/or psychotic symptoms associated with AD; iii) evaluating diagnostic and predictive utility of varied structural (MRI) and functional (fMRI, PET) imaging modalities in patients with a spectrum of cognitive deficits, from AD, mild cognitive impairment (MCI), to healthy control subjects: to determine their clinical usefulness.
3- Examining the role of the immune system in affective and neuropsychiatric disorders, including: i) examining the interface between peripheral catecholamines and the immune system by measuring cytokine plasma levels during an IV epinephrine challenge in healthy and depressed individuals; ii) Using O15 PET functional brain imaging, examining the effect of peripherally stimulating the immune system with IV Lipopolysaccharide (LPS) on the nature and time course of CNS blood flow changes.
4- Clinical psychopharmacology practice
Undergraduate: University. of Pittsburgh, B.S., 1982
Medical School: Columbia University, M.D., 1990
Internship: Yale University, Psychiatry, 1990 - 1991
Residency: Yale University, Psychiatry, 1991 - 1994
Fellowship: Yale University, Neuroscience, 1994 - 1996
Post-Graduate: New York State Psychiatric Institute GERIATRIC Psychiatry, Fellowship, 1999 - 2001
Board Certifications: American Board of Psychiatry and Neurology
Subspeciality Certifications: Behavioral Neurology and Neuropsychiatry
• Behavioral Neurology
NYS Psychiatric Institute
Room 2714 Unit/Box:126
1051 Riverside Drive
New York, NY 10032
I am interested in optimizing the longterm quality of life in adults and elderly patients with depression and memory complaints through research applying new lab findings to clinical patient care. In the same population, characterizing the immune-brain bi-directional relationship and its' role in affective and neurodegenerative disorders.
1. Pelton GH, Harper OL, Tabert MH, Sackeim HA, Scarmeas N, Roose SP, Devanand DP: Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study. Int J Geriatr Psychiatry 2007;12
2. Tabert MH, Manley JJ, Liu X, Pelton GH, Rosenblum S, Jacobs M, Zamora D, Goodkind M, Bell K, Stern Y, Devanand DP: Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Arch Gen Psychiatry 2006;63: 916-24
3. Devanand DP, Habeck CG, Tabert MH, Scarmeas N, Pelton GH, Moeller JM, Mensh BD, Tarabula T, Van Heertum RL, Stern Y: PET Network Abnormalities and Cognitive Decline in Patients with Mild Cognitive Impairment. Neuropsychopharmacology 2006;31: 1327-34
4. Pelton GH: Psychiatric Diagnosis and Management of Psychosis in Dementia”. In Hand Book of Dementia: Psychological, Neurological, and Psychiatric Perspectives, Wiley & Sons, Inc., Hoboken, NJ, USA
5. Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, Gupta S, Colon S, Schimming C, Pelton GH, Levin B: Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med 2012;16: 1497-507